The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular oedema

dc.contributor.author	Cicinelli, M.V.
dc.contributor.author	Rosenblatt, A.
dc.contributor.author	Grosso, D.
dc.contributor.author	Zollet, P.
dc.contributor.author	Capone, L.
dc.contributor.author	Rabiolo, A.
dc.contributor.author	Lattanzio, R.
dc.contributor.author	Loewenstein, A.
dc.contributor.author	Bandello, F.
dc.contributor.author	Nassisi, M.
dc.contributor.author	Tan, A.
dc.date.accessioned	2021-12-21T08:40:28Z
dc.date.available	2021-12-21T08:40:28Z
dc.date.issued	2021
dc.identifier.issn	0950222X
dc.identifier.uri	https://doi.org/10.1038/s41433-020-01373-1
dc.identifier.uri	http://dspace.yeniyuzyil.edu.tr:8080/xmlui/handle/20.500.12629/1003
dc.description.abstract	Background/Objectives: To investigate if the visual and anatomic response to the first dexamethasone implant (DEX) predicts the 12-month clinical outcome after shifting to fluocinolone acetonide (FAc) implant in patients with diabetic macular oedema (DMO)
dc.language.iso	English
dc.publisher	Springer Nature
dc.title	The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular oedema
dc.type	Article
dc.relation.journal	Eye (Basingstoke)
dc.identifier.issue	12
dc.identifier.startpage	3232
dc.identifier.endpage	3242
dc.identifier.volume	35
dc.identifier.doi	10.1038/s41433-020-01373-1
dc.relation.issue	12
dc.relation.volume	35